Home About Wiki

Ab Hominem

FDA Approved Antibodies

OfficialName Name Target Indication Original Approval
ORTHOCLONE OKT3 Muromonab CD3 CD3 Transplants 1985
CEA-SCAN Arcitumomab CD66(CEA) Cancer 1996
MYOSCINT Imciromab CardiacMyosin Other 1996
MYLOTARG Gemtuzumab ozogamicin CD33 Cancer 2000
PROSTASCINT Capromab pendetide PSMA Cancer 1996
VERLUMA Nofetumomab merpentan EpCAM+CD20 Cancer 1996
REOPRO Abciximab CD41(Integrin-α2β) Other 1997
RITUXAN Rituximab CD20 Autoimmunity + Cancer 1997
ZENPAX Daclizumab CD25(IL-2Rα) Transplants 1997
ENBREL Etanercept TNFα Autoimmunity 1998
HERCEPTIN Trastuzumab CD340(HER2) Cancer 1998
REMICADE Infliximab TNFα Autoimmunity 1998
SIMULECT Basiliximab CD25(IL-2Rα) Transplants 1998
SYNAGIS Palivizumab Fprotein(RSV) Infection 1998
LEMTRADA Alemtuzumab CD52 Cancer 2001
CAMPATH Alemtuzumab CD52 Autoimmunity 2001
HUMIRA Adalimumab TNFα Autoimmunity 2002
ZEVALIN Ibritumomab tiuxetan CD20 Cancer 2002
AMEVIVE Alefacept CD2 Autoimmunity 2003
BEXXAR Tositumomab CD20 Cancer 2003
RAPTIVA Efalizumab CD11a(LFA-1) Autoimmunity 2003
XOLAIR Omalizumab IgE-Fc Autoimmunity 2003
NEUTROSPEC fanolesomab CD15 Other 2004
AVASTIN Bevacizumab VEGF-A Cancer 2004
ERBITUX Cetuximab EGFR Cancer 2004
TYSABRI Natalizumab Integrin-α4 Autoimmunity 2004
ORENCIA Abatacept CD80+CD86 Autoimmunity 2005
LUCENTIS Ranibizumab VEGF-A Other 2006
VECTIBIX Panitumumab EGFR Cancer 2006
SOLIRIS Eculizumab C5 Other 2007
ARCALYST Rilonacept IL-1 Other 2008
CIMZIA Certolizumab pegol TNFα Autoimmunity 2008
NPLATE Romiplostim CD110 Other 2008
ARZERRA Ofatumumab CD20 Cancer 2009
ILARIS Canakinumab IL-1b Other 2009
REMOVAB Catumaxomab EpCAM+CD3 Cancer 2009 EMA
SIMPONI Golimumab TNFα Autoimmunity 2009
SIMPONI ARIA Golimumab TNFα Autoimmunity 2009
STELARA Ustekinumab IL-12+IL-23 Autoimmunity 2009
ACTEMRA Tocilizumab CD126(IL-6R) Autoimmunity + Cancer 2010
PROLIA Denosumab CD254(RANKL) Other 2010
XGEVA Denosumab CD254(RANKL) Cancer 2010
ADCETRIS Brentuximab vedotin CD30(TNFRSF8) Cancer 2011
BENLYSTA Belimumab CD257(BAFF) Autoimmunity 2011
NULOJIX Belatacept CD80+CD86 Transplants 2011
YERVOY Ipilimumab CD152(CTLA-4) Cancer 2011
PERJETA Pertuzumab CD340(HER2) Cancer 2012
RAXIBACUMAB Raxibacumab Anthrax Infection 2012
GAZYVA Obinutuzumab CD20 Cancer 2013
KADCYLA Ado Trastuzumab emtansine CD340(HER2) Cancer 2013
BLINCYTO Blinatumomab CD19+CD3 Cancer 2014
CYRAMZA Ramucirumab VEGFR2 Cancer 2014
ENTYVIO Vedolizumab Integrin-α4β7 Autoimmunity 2014
KEYTRUDA Pembrolizumab CD279(PD-1) Cancer 2014
OPDIVO Nivolumab CD279(PD-1) Cancer 2014
SYLVANT Siltuximab IL-6 Other 2014
COSENTYX Secukinumab IL-17α Autoimmunity 2015
DARZALEX Daratumumab CD38 Cancer 2015
EMPLICITI Elotuzumab CD319(SLAMF7) Cancer 2015
NUCALA Mepolizumab IL-5 Autoimmunity 2015
PORTRAZZA Necitumumab EGFR Cancer 2015
PRALUENT Alirocumab PCSK9 Other 2015
PRAXBIND Idarucizumab Dabigatran Other 2015
REPATHA Evolocumab PCSK9 Other 2015
UNITUXIN Dinutuximab GD2 Cancer 2015
ZINBRYTA Daclizumab CD25(IL-2Rα) Autoimmunity 2016
AMJEVITA Adalimumab atto TNFα Autoimmunity 2016
ANTHIM Obiltoxaximab Anthrax Infection 2016
CINQUAIR Reslizumab IL-5 Autoimmunity 2016
INFLECTRA Infliximab dyyb TNFα Autoimmunity 2016
LARTRUVO Olaratumab PDGFRα Cancer 2016
TALTZ Ixekizumab IL-17α Autoimmunity 2016
TECENTRIQ Atezolizumab CD274(PD-L1) Cancer 2016
ZINPLAVA Bezlotoxumab Toxin-B Infection 2016
BAVENCIO Avelumab CD274(PD-L1) Cancer 2017
DUPIXENT Dupliumab IL-4Rα Autoimmunity 2017
OCREVUS Ocrelizumab CD20 Autoimmunity 2017
SILIQ Brodalumab IL-17R Autoimmunity 2017
MVASI Bevacizumab awwb VEGF-A Cancer 2017
BESPONSA Inotuzumab ozogamicin CD22 Cancer 2017
CYLTEZO Adalimumab adbm TNFα Autoimmunity 2017
IMFINZI Durvalumab CD274(PD-L1) Cancer 2017
KEVZARA Sarilumab CD126(IL-6R) Autoimmunity 2017
RENFLEXIS Infliximab abda TNFα Autoimmunity 2017
RITUXAN HYCELA Rituximab hyaluronidase CD20 Cancer 2017
TREMFYA Guselkumab IL-23α Autoimmunity 2017
FASENRA Benralizumab IL-5Rα Autoimmunity 2017
HEMLIBRA Emicizumab kxwh FactorIXa+FactorX Hemophilia 2017
OGIVRI Trastuzumab dkst CD340(HER2) Cancer 2017
IXIFI Infliximab qbtx TNFα Autoimmunity 2017
   
Updated of 2017-12-23